English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Bergenbio Asa
Press release submission
| Jun 14, 2019
BERGENBIO ASA: BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy
Trending
+
Pharmaceuticals
Patient Daily
| Jun 30, 2025
PhRMA public affairs senior director on 340B program: 'PBMs took $140 billion in rebates and fees, driving up American medicine costs'
+
Pharmaceuticals
Patient Daily
| Jul 1, 2025
PhRMA chief public affairs officer on 340B drug pricing: ‘Lowering drug prices for U.S. patients starts by reining in middlemen’
+
Pharmaceuticals
Patient Daily
| Jun 25, 2025
Neurosurgeon at the University of California: ‘340B is being exploited for profit, not patient care’
